Andrus Miranda R, Holloway Katherine P, Clark Deidre B
Harrison School of Pharmacy, Auburn University, Tuscaloosa, AL, USA.
Ann Pharmacother. 2004 Jan;38(1):142-5. doi: 10.1345/aph.1D113.
To evaluate the safety and cardiovascular benefits of beta-blocker therapy in patients with chronic obstructive pulmonary disease (COPD).
Clinical literature was accessed through MEDLINE (1966-February 2003). Key search terms included chronic obstructive pulmonary disease and adrenergic beta-antagonists.
beta-Blockers are often avoided in patients with COPD because of fear of bronchoconstriction, despite the known cardiovascular mortality benefits. A review of studies evaluating the use of beta-blockers in COPD was undertaken.
The literature supports the safety and mortality benefits of using beta-blockers in COPD. Patients with mild to moderate COPD should receive cardioselective beta-blocker therapy when a strong indication exists.
评估β受体阻滞剂治疗慢性阻塞性肺疾病（COPD）患者的安全性及心血管获益情况。
通过MEDLINE（1966年 - 2003年2月）检索临床文献。关键检索词包括慢性阻塞性肺疾病和肾上腺素能β拮抗剂。
尽管已知β受体阻滞剂对心血管疾病死亡率有益，但由于担心支气管收缩，COPD患者常避免使用此类药物。本研究对评估COPD患者使用β受体阻滞剂的研究进行了综述。
文献支持在COPD患者中使用β受体阻滞剂的安全性及死亡率获益情况。存在明确指征时，轻至中度COPD患者应接受心脏选择性β受体阻滞剂治疗。
